AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31898518 — intervention group
Group type: COMPARATOR
Intervention: Standard Diet (SD) as recommended by the German Nutrition Society
Number of subjects: 111
Study 31898518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 111
Study 31898518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Diet (FD)
Number of subjects: 111
Study 31898518 — intervention group
Group type: COMPARATOR
Intervention: Standard Diet (SD)
Number of subjects: 111
Study 30661948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 48
Study 30661948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE) with CGD
Number of subjects: 48
Study 27990717 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron
Number of subjects: 70
Study 27990717 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 70
Study 25967531 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular orthosis
Number of subjects: 47
Study 25967531 — intervention group
Group type: COMPARATOR
Intervention: Invariable orthosis
Number of subjects: 47
Study 23842003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib vaccination via vastus lateralis muscle (2 or 3 times at monthly intervals)
Number of subjects: 320
Study 23842003 — intervention group
Group type: COMPARATOR
Intervention: Hib vaccination via vastus lateralis muscle (3 times for 2-5 mo group, 2 times for 6-12 mo group)
Number of subjects: 320
Study 23842003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib vaccination via vastus lateralis muscle
Number of subjects: 320
Study 23842003 — intervention group
Group type: COMPARATOR
Intervention: Hib vaccination via deltoid muscle
Number of subjects: 320
Study 22216717 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen 2 mg/kg
Number of subjects: 52
Study 22216717 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen 5 mg/kg
Number of subjects: 52
Study 22216717 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen 10 mg/kg
Number of subjects: 52
Study 22216717 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (all doses combined)
Number of subjects: 52
Study 22216717 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 52
Study 18640631 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrapped warm footbath (WW Footbath)
Number of subjects: 13
Study 18640631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 13
Study 16289322 — intervention group
Group type: EXPERIMENTAL
Intervention: Down's syndrome (DS)
Number of subjects: 0
Study 16289322 — intervention group
Group type: COMPARATOR
Intervention: Mental retardation (MR)
Number of subjects: 0
Study 16289322 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 0
Study 14560413 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon polyethylene liners (cross-linked with 5.0 Mrad of gamma irradiation)
Number of subjects: 0
Study 14560413 — intervention group
Group type: COMPARATOR
Intervention: Non-cross-linked polyethylene
Number of subjects: 0
Study 14674205 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training programme for four months
Number of subjects: 77
Study 8985763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 1796
Study 8985763 — intervention group
Group type: COMPARATOR
Intervention: Concurrent control (unintentionally not treated)
Number of subjects: 1796
Study 1451552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPLX)
Number of subjects: 10
Study 1451552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (OFLX)
Number of subjects: 10
Study 1451552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefloxacin (NFLX)
Number of subjects: 10
Study 1451552 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin (ENX)
Number of subjects: 10
Study 3965692 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana cigarette (1.83% delta 9‐tetrahydrocannabinol)
Number of subjects: 16
Study 3965692 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 16
Study 31066486 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfur‐sodium sulfacetamide combination
Number of subjects: 72
Study 31066486 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% crotamiton
Number of subjects: 72
Study 31066486 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% permethrin
Number of subjects: 72
Study 29024454 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA)
Number of subjects: 238
Study 29024454 — intervention group
Group type: COMPARATOR
Intervention: Standard RA education (comparison group)
Number of subjects: 238
Study 27114420 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 87
Study 25042302 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy plus topical analgesic
Number of subjects: 20
Study 25042302 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy
Number of subjects: 20
Study 22313547 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose venlafaxine xr (up to 300 mg/day) with problem solving therapy for depression and pain (PST-DP)
Number of subjects: 0
Study 22313547 — intervention group
Group type: COMPARATOR
Intervention: High-dose venlafaxine xr (up to 300 mg/day) and continued supportive management (SM)
Number of subjects: 0
Study 22313547 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment with venlafaxine xr 150 mg/day and supportive management (SM)
Number of subjects: 0
Study 20049491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBT) 300 mg
Number of subjects: 40
Study 20049491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (ROP) 0.5 mg
Number of subjects: 40
Study 20049491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17329045 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 107
Study 17329045 — intervention group
Group type: COMPARATOR
Intervention: LNG-IUS
Number of subjects: 107
Study 16293863 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus paclitaxel (EP) - epirubicin 75 mg/m2 and paclitaxel 200 mg/m2
Number of subjects: 705
Study 16293863 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin plus cyclophosphamide (EC) - epirubicin 75 mg/m2 and cyclophosphamide 600 mg/m2
Number of subjects: 705
Study 16293863 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus paclitaxel (EP)
Number of subjects: 705
Study 16293863 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin plus cyclophosphamide (EC)
Number of subjects: 705
Study 11955904 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia
Number of subjects: 78
Study 11955904 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia combined with intracameral lidocaine 1%
Number of subjects: 78
Study 8602382 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 20
Study 8602382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g 4 times/day
Number of subjects: 20
Study 8602382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime plus sucralfate 1 g 4 times/day
Number of subjects: 20
Study 2655671 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (Narcan)
Number of subjects: 1
Study 2655671 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (Trexan)
Number of subjects: 1
Study 2655671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 871282 — intervention group
Group type: EXPERIMENTAL
Intervention: Improperly fitted mask (Group I and II)
Number of subjects: 17
Study 871282 — intervention group
Group type: EXPERIMENTAL
Intervention: Properly fitted mask (Group III)
Number of subjects: 17
Study 871282 — intervention group
Group type: EXPERIMENTAL
Intervention: USAF aviator MBU‐5/P mask and A‐14 regulator
Number of subjects: 17
Study 871282 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial blood gas measurements
Number of subjects: 17
Study 871282 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary data from tissue oxygen measurements
Number of subjects: 17
Study 31786154 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 7.5 mg
Number of subjects: 167
Study 31786154 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 167
Study 31786154 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 167
Study 31786154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 30946378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood (ILIB)
Number of subjects: 44
Study 30946378 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 28266301 — intervention group
Group type: EXPERIMENTAL
Intervention: Written invitation to undergo testing of the stool for blood with an accompanying test
Number of subjects: 35384
Study 28266301 — intervention group
Group type: COMPARATOR
Intervention: Written invitation to undergo testing of the stool for blood without an accompanying test
Number of subjects: 35384
Study 28266301 — intervention group
Group type: EXPERIMENTAL
Intervention: Written invitation to undergo colonoscopic screening
Number of subjects: 35384
Study 25757725 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified hatha yoga training (HYG: n = 9)
Number of subjects: 18
Study 25757725 — intervention group
Group type: COMPARATOR
Intervention: Control group with no yoga training (CG: n = 9)
Number of subjects: 18
Study 23619372 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfused symptomatic infants (Hct<0.30, n=32)
Number of subjects: 48
Study 23619372 — intervention group
Group type: COMPARATOR
Intervention: Non transfused asymptomatic controls (Hct >0.30, n=9)
Number of subjects: 48
Study 23619372 — intervention group
Group type: COMPARATOR
Intervention: Non transfused asymptomatic controls (Hct <0.30, n=7)
Number of subjects: 48
Study 21330161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone condensing technique
Number of subjects: 48
Study 21330161 — intervention group
Group type: COMPARATOR
Intervention: Standard drilling technique
Number of subjects: 48
Study 19454518 — intervention group
Group type: EXPERIMENTAL
Intervention: Puragen
Number of subjects: 68
Study 19454518 — intervention group
Group type: COMPARATOR
Intervention: Captique
Number of subjects: 68
Study 16696806 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mL white wine
Number of subjects: 25
Study 16696806 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL beer
Number of subjects: 25
Study 16696806 — intervention group
Group type: COMPARATOR
Intervention: tap water (control)
Number of subjects: 25
Study 15155043 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ALERT intervention (11 lessons in Grade 7 and 3 lessons in Grade 8)
Number of subjects: 4276
Study 15155043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4276
Study 11052433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (100 mg administered 2 minutes before releasing the aortic cross-clamp)
Number of subjects: 34
Study 11052433 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (5 mL administered to control group)
Number of subjects: 34
Study 11052433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (100 mg)
Number of subjects: 34
Study 11052433 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (5 mL)
Number of subjects: 34
Study 9120797 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (bicycle ergometer, 80% AT, 10 min, 2 times a day for 2 weeks from the 15th day)
Number of subjects: 20
Study 9120797 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (non-training group)
Number of subjects: 20
Study 7801557 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential x-ray diagnosis of respiratory distress syndrome
Number of subjects: 93
Study 3680471 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 28
Study 3680471 — intervention group
Group type: COMPARATOR
Intervention: Seven-point Likert scale
Number of subjects: 28
Study 30360984 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-FA 3 × 1 g/day
Number of subjects: 16
Study 30360984 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 16
Study 30251638 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid nasal barrier dressing during CPAP
Number of subjects: 108
Study 30251638 — intervention group
Group type: COMPARATOR
Intervention: No barrier dressing during CPAP
Number of subjects: 108
Study 27223128 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic azithromycin
Number of subjects: 24
Study 27223128 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions, subgingival scaling and root planing
Number of subjects: 24
Study 24502959 — intervention group
Group type: EXPERIMENTAL
Intervention: PKEP
Number of subjects: 160
Study 22075372 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture on ST‐36 and ST‐39
Number of subjects: 43
Study 22075372 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture on ST‐36 and ST‐39
Number of subjects: 43
Study 22075372 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture on nonacupoints
Number of subjects: 43
Study 22075372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 21064034 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2a and ribavirin therapy
Number of subjects: 1778
Study 17582563 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 908
Number of subjects: 0
Study 17582563 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 908-htrA
Number of subjects: 0
Study 17582563 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 909
Number of subjects: 0
Study 17582563 — intervention group
Group type: COMPARATOR
Intervention: Ty21a (Vivotif)
Number of subjects: 0
Study 17582563 — intervention group
Group type: COMPARATOR
Intervention: Vi polysaccharide vaccine (Typhim Vi)
Number of subjects: 0
Study 16128675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 44
Study 16128675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12399074 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation (folic acid 0.4 mg, pyridoxine 120 mg, riboflavin 75 mg per day for 30 days)
Number of subjects: 33
Study 12399074 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation
Number of subjects: 33
Study 10454691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg taken orally every 4 hours)
Number of subjects: 21
Study 10454691 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (6 g bolus and 2 g/hr intravenous infusion)
Number of subjects: 21
Study 8521886 — intervention group
Group type: EXPERIMENTAL
Intervention: Firm stents (polyurethane)
Number of subjects: 155
Study 8521886 — intervention group
Group type: COMPARATOR
Intervention: Soft stents (Sof‐Flex)
Number of subjects: 155
Study 2699823 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 30
Study 2699823 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg buspirone
Number of subjects: 30
Study 2699823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 606778 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-virus or whole-virus preparations of killed, monovalent influenza A/New Jersey/76 virus vaccine
Number of subjects: 133
Study 606778 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of split-virus or whole-virus preparations of killed, monovalent influenza A/New Jersey/76 virus vaccine
Number of subjects: 133
Study 606778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 31826815 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication (LF)
Number of subjects: 55
Study 31826815 — intervention group
Group type: COMPARATOR
Intervention: Open fundoplication (OF)
Number of subjects: 55
Study 30822531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 178
Study 30822531 — intervention group
Group type: COMPARATOR
Intervention: Passive Scattering Proton Therapy (PSPT)
Number of subjects: 178
Study 28065872 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cervical transfacet fusion
Number of subjects: 80
Study 28065872 — intervention group
Group type: COMPARATOR
Intervention: Mechanical cervical tractions
Number of subjects: 80
Study 25596476 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance tocolysis with nifedipine (exact dosage and duration not specified)
Number of subjects: 0
Study 23663341 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of remifemin (one tablet twice daily) and paroxetine (20 mg once daily) for 2 months
Number of subjects: 120
Study 23663341 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20 mg once daily) for 2 months
Number of subjects: 120
Study 21865351 — intervention group
Group type: COMPARATOR
Intervention: Placebo during fasting
Number of subjects: 7
Study 21865351 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin during fasting
Number of subjects: 7
Study 21865351 — intervention group
Group type: COMPARATOR
Intervention: Baseline/isocaloric diet
Number of subjects: 7
Study 18949459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (n = 19; mean ketamine blood plasma = 175.29 ng/mL)
Number of subjects: 30
Study 18949459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 30
Study 17109338 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC vCP1452
Number of subjects: 81
Study 17109338 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus vaccine
Number of subjects: 81
Study 17109338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 14742176 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic retrieval under dual-task conditions
Number of subjects: 0
Study 14742176 — intervention group
Group type: COMPARATOR
Intervention: Semantic retrieval under dual-task conditions
Number of subjects: 0
Study 14742176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued recall (Experiment 1)
Number of subjects: 0
Study 14742176 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition (Experiment 2)
Number of subjects: 0
Study 11688615 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed information recommending folate intake to decrease the risk of NTDs disseminated in 1997
Number of subjects: 1196
Study 9778002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.4 ng/ml (group LS)
Number of subjects: 66
Study 9778002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.8 ng/ml (group MS)
Number of subjects: 66
Study 9778002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.2 ng/ml (group HS)
Number of subjects: 66
Study 9778002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 ng/ml (group LF)
Number of subjects: 66
Study 9778002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 ng/ml (group MF)
Number of subjects: 66
Study 9778002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 ng/ml (group HF)
Number of subjects: 66
Study 9778002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil concentrations > or = 1.25 +/- 0.21 ng/ml
Number of subjects: 66
Study 9778002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl concentrations > or = 13.3 +/- 2.2 ng/ml
Number of subjects: 66
Study 9778002 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 66
Study 9778002 — intervention group
Group type: COMPARATOR
Intervention: Hemodynamics
Number of subjects: 66
Study 7869005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent catheterization
Number of subjects: 98
Study 7869005 — intervention group
Group type: COMPARATOR
Intervention: Indwelling catheterization
Number of subjects: 98
Study 3280855 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 81
Study 3280855 — intervention group
Group type: COMPARATOR
Intervention: Aluminum-containing compounds
Number of subjects: 81
Study 29474190 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization of ferrogels and magnetorheological elastomers
Number of subjects: 0
Study 29474190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic moduli with increasing magnetization
Number of subjects: 0
Study 27797282 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP technique
Number of subjects: 155
Study 27797282 — intervention group
Group type: COMPARATOR
Intervention: Standard needle injection
Number of subjects: 155
Study 26267861 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation (1 mA) over the left dorsolateral prefrontal cortex
Number of subjects: 30
Study 26267861 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 24183743 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 61
Study 24183743 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 61
Study 21936930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (LiCO3) plus riluzole
Number of subjects: 220
Study 21936930 — intervention group
Group type: COMPARATOR
Intervention: Riluzole alone
Number of subjects: 220
Study 17995967 — intervention group
Group type: EXPERIMENTAL
Intervention: LED system (120 mW cm(‐2); 40 J cm(‐2), LEDA, WaveLight AG, Erlangen, Germany)
Number of subjects: 17
Study 17995967 — intervention group
Group type: COMPARATOR
Intervention: Incoherent lamp (160 mW cm(‐2); 100 J cm(‐2), PDT 1200L, Waldmann Medizintechnik, Villingen‐Schwenningen, Germany)
Number of subjects: 17
Study 17995967 — intervention group
Group type: EXPERIMENTAL
Intervention: LED system
Number of subjects: 17
Study 17995967 — intervention group
Group type: COMPARATOR
Intervention: Incoherent lamp
Number of subjects: 17
Study 16644612 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine once-daily 16 mg (M16)
Number of subjects: 666
Study 16644612 — intervention group
Group type: COMPARATOR
Intervention: Molsidomine twice-daily 8 mg (M8)
Number of subjects: 666